Dear Colleague,
Please find attached a letter being HSCB today in relation to the Opioid Substitution Treatment service from community pharmacies.
Kind regards,

SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
Dear Colleague,
Further concessionary prices have been granted for March 2020:
Drug | Pack Size | Concessionary Price |
Amiloride 5mg tablets | 28 | £27.50 |
Clonidine 25microgram tablets | 112 | £14.44 |
Co-careldopa 25mg/100mg tablets | 100 | £12.88 |
Cyanocobalamin 50microgram tablets | 50 | £9.84 |
Desmopressin 200microgram tablets | 30 | £22.70 |
Esomeprazole 20mg gastro-resistant capsules | 28 | £2.42 |
Fluoxetine 10mg capsules | 30 | £46.70 |
Fluoxetine 60mg capsules | 30 | £6.99 |
Lamotrigine 25mg dispersible tablets sugar free | 56 | £7.74 |
Meloxicam 7.5mg tablets | 30 | £3.15 |
Meloxicam 15mg tablets | 30 | £5.80 |
Perindopril erbumine 4mg tablets | 30 | £4.30 |
Pizotifen 1.5mg tablets | 28 | £5.35 |
Ranitidine 150mg tablets | 60 | £7.32 |
Ranitidine 300mg tablets | 30 | £6.80 |
Tacrolimus 0.1% ointment | 30g | £18.20 |
Tolterodine 1mg tablets | 56 | £22.80 |
Tolterodine 2mg tablets | 56 | £23.99 |
Venlafaxine 75mg tablets | 56 | £14.22 |
Kind regards,
Katherine
SENT FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy Development
Dear Colleague,
COVID-19 Community Pharmacy Social Media Cards
CPNI has prepared a selection of community pharmacy social media cards with COVID -19 specific messages which contractors can add to their social media channels. In addition to CPNI’s ongoing print and broadcast media activity, these resources are to help the public fully appreciate the pressurised environment the network is working in. These include messages calling for their assistance in reducing the risk of transmission of COVID-19 and asking for patience when they visit a pharmacy.
I have attached a selection, but all the cards can be accessed by downloading this link: https://wetransfer.com/downloads/b8edbfd5bee1253055a141b05a30f97420200317154135/d79fbd3de790f4e95d7e9a557961987820200317154137/eb265b
To help increase the reach of these messages, I would ask you to please share these cards with all your staff members. Just in the last few days, contractors and pharmacy teams have helped to share these resources and associated news pieces extensively on social media.
Thank-you.
Yours sincerely
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
Dear Colleague,
Peter Rice, CPNI Vice Chair and I briefed the Northern Ireland Health Committee yesterday on community pharmacy’s response to COVID 19.
It was an opportunity to update committee members on the extreme and unrelenting pressures community pharmacy teams are experiencing on a daily basis and to highlight some of the measures you have implemented to help continue the safe supply of medicines to the public.
You can listen again here – It begins at 1:13:24.
Yours sincerely
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
Dear Colleague
Signing for deliveries of controlled drugs and other medicines
There have been some issues raised in respect of the signing for controlled drugs and other medicines.
Please find attached a letter sent from Mr Canice Ward to the Northern Ireland wholesale dealers, which helpfully recognises that in the current situation it may be necessary to deviate from the normal procedure in respect of signing for deliveries of medicines.
The guidance indicates that it would be acceptable if alternative arrangements are implemented for the signing for orders (including those for controlled drugs), provided these interim measures can verify that the products have been delivered.
Action
Contractors should:
CPNI will continue to advise and support you in the weeks to come.
Yours sincerely
Mike
Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs
Dear Colleague,
Letter from Cathy Harrison, CPO to Contractors re: COVID-19
Please see the attached letter from Cathy Harrison.
Do not hesitate to contact CPNI office or your local CPNI director if you require any additional information.
Yours sincerely
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive